FDA 483 - Northland Nuclear Medicine, LLC - June 07, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Northland Nuclear Medicine, LLC in Bismarck, ND, a manufacturer of PET drugs, revealed significant deficiencies. The firm lacked adequate production and process controls, including issues with aseptic process simulations, data integrity, and vendor qualification. Additionally, critical equipment was not properly qualified, and master production records were incomplete, raising concerns about the consistent quality and purity of their 18F-FDG product.
ID · 7a92875d-0ef0-44bc-b02c-acbc7e748a4c